Review
Aug 2026
The 21-gene recurrence score assay as a tool for predicting recurrence risk and guiding adjuvant treatment selection in early breast cancer
Oncotype DX has strong prognostic evidence and has meaningfully reduced chemotherapy use, though its case as a biomarker predictive of therapeutic effect from chemotherapy rests on trial designs with important limitations.
C. Martínez-Pérez, G. Tramonti, C. Kay et al.
· Expert Review of Molecular D... · 0 citations